In this multicenter, assessor-blinded, cluster randomized clinical trial involving 1,075 participants across 289 households with dermoscopy-confirmed classic scabies, oral ivermectin 200 µg/kg given on days 0 and 10 failed to demonstrate noninferiority to topical 5% permethrin cream for clinical cure at day 28. Cluster-level cure rates were significantly higher with permethrin vs ivermectin, supporting permethrin as the preferred first-line therapy in children and adults when topical treatment is feasible.

Source: The BMJ